



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

3. Pharmaceutical form

White coloured, capsule shaped, biconvex both side plain film coated tablets.

4. Clinical particulars

4.1 Therapeutic Indication:

Co-Amoxiclav is indicated for the treatment of the following infections in adults and children

- Acute bacterial sinusitis (properly diagnosed)
- Cystitis
- Pyelonephritis
- Cellulitis
- Animal bites
- Severe dental abscess with spreading cellulitis.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Contraindications

Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid.

4.3 Special warnings and precautions for use:

Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents.

Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.

In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.

This presentation of Co-Amoxiclav is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents, that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid (e.g. penicillin-insusceptible *S. pneumoniae*).

Convulsions may occur in patients with impaired renal function or in those receiving high doses (see section 4.8).

Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.

Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.

Prolonged use may occasionally result in overgrowth of non-susceptible organisms.

The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemouspustulosis (AGEP) (see Section 4.8). This reaction requires discontinuation of Co-Amoxiclav and contra-indicates any subsequent administration of amoxicillin.

Amoxicillin/clavulanic acid should be used with caution in patients with evidence of hepatic impairment (see sections 4.2, 4.3 and 4.8).

Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. In all populations, signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

severe and, in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects (see section 4.8).

Antibiotic-associated colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life threatening (see section 4.8). Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Should antibiotic-associated colitis occur, amoxicillin/clavulanic acid should immediately be discontinued, a physician be consulted and an appropriate therapy initiated. Anti-peristaltic medicinal products are contraindicated in this situation.

Periodic assessment of organ system functions, including renal, hepatic and haematopoietic function is advisable during prolonged therapy.

Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin/clavulanic acid. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see section 4.5 and 4.8).

In patients with renal impairment, the dose should be adjusted according to the degree of impairment (see section 4.2).

In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria. In patients with bladder catheters, a regular check of patency should be maintained (see section 4.9).

During treatment with amoxicillin, enzymatic glucose oxidase methods should be used whenever testing for the presence of glucose in urine because false positive results may occur with non-enzymatic methods.

The presence of clavulanic acid in Co-Amoxiclav may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

There have been reports of positive test results using the Bio-Rad Laboratories Platelia *Aspergillus* EIA test in patients receiving amoxicillin/clavulanic acid who were subsequently found to be free of *Aspergillus* infection. Cross-reactions with non-*Aspergillus* polysaccharides and polyfuranoses with Bio-Rad Laboratories Platelia *Aspergillus* EIA test have been reported. Therefore, positive test results in patients receiving amoxicillin/clavulanic acid should be interpreted cautiously and confirmed by other diagnostic methods.

4.4 Interaction with other medicinal products and other forms of interaction

Oral anticoagulants

Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary (see sections 4.4 and 4.8).

Methotrexate

Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.

Probenecid

Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.

Mycophenolatemofetil

In patients receiving mycophenolatemofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolatemofetil should not normally be necessary in the absence of



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.

4.5 Adverse Drug Reactions

The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and vomiting.

The ADRs derived from clinical studies and post-marketing surveillance with Co-Amoxiclav are sorted by MedDRA System Organ Class, are listed below.

The following terminologies have been used in order to classify the occurrence of undesirable effects.

Very common ($\geq 1/10$)

Common ($\geq 1/100$ to $< 1/10$)

Uncommon ($\geq 1/1,000$ to $< 1/100$)

Rare ($\geq 1/10,000$ to $< 1/1,000$)

Very rare ($< 1/10,000$)

Not known (cannot be estimated from the available data)

<u>Infections and infestations</u>	
Mucocutaneous candidosis	Common
Overgrowth of non-susceptible organisms	Not known
<u>Blood and lymphatic system disorders</u>	
Reversible leucopenia (including neutropenia)	Rare
Thrombocytopenia	Rare
Reversible agranulocytosis	Not known
Haemolytic anaemia	Not known
Prolongation of bleeding time and prothrombin time ¹	Not known



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

Immune system disorders¹⁰

Angioneurotic oedema	Not known
Anaphylaxis	Not known
Serum sickness-like syndrome	Not known
Hypersensitivity vasculitis	Not known

Nervous system disorders

Dizziness	Uncommon
Headache	Uncommon
Reversible hyperactivity	Not known
Convulsions ²	Not known
Aseptic meningitis	Not known

Gastrointestinal disorders

Diarrhoea	Very common
Nausea ³	Common
Vomiting	Common
Indigestion	Uncommon
Antibiotic-associated colitis ⁴	Not known
Black hairy tongue	Not known

Hepatobiliary disorders

Rises in AST and/or ALT ⁵	Uncommon
Hepatitis ⁶	Not known
Cholestatic jaundice ⁶	Not known

Skin and subcutaneous tissue disorders⁷

Skin rash	Uncommon
Pruritus	Uncommon
Urticaria	Uncommon
Erythema multiforme	Rare
Drug reaction with eosinophilia and	Not known



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

systemic symptoms (DRESS)	
Stevens-Johnson syndrome	Not known
Toxic epidermal necrolysis	Not known
Bullous exfoliative-dermatitis	Not known
Acute generalised exanthemouspustulosis (AGEP) ⁹	Not known
<u>Renal and urinary disorders</u>	
Interstitial nephritis	Not known
Crystalluria ⁸	Not known
¹ See section 4.4 ² See section 4.4. ³ Nausea is more often associated with higher oral doses. If gastrointestinal reactions are evident, they may be reduced by taking amoxicillin/clavulanic acid at the start of a meal. ⁴ Including pseudomembranous colitis and haemorrhagic colitis (see section 4.4) ⁵ A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown. ⁶ These events have been noted with other penicillins and cephalosporins (see section 4.4). ⁷ If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued (see section 4.4). ⁸ See section 4.9 ⁹ See section 4.4 ¹⁰ See sections 4.3 and 4.4	

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme (www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

5. Pharmacological properties



5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors;
ATC code: J01CR02.

Mode of action

Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lyses and cell death.

Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.

Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.

PK/PD relationship

The time above the minimum inhibitory concentration ($T > MIC$) is considered to be the major determinant of efficacy for amoxicillin.

Mechanisms of resistance

The two main mechanisms of resistance in Co-Amoxiclav are:

- the inactivation by bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.
- alteration of the PBPs, which reduce the affinity of the antibacterial agent for the target.

Impermeability of bacteria or efflux pump mechanisms may cause / contribute to the bacterial resistance particularly in Gram-negative bacteria.

Breakpoints

MIC breakpoints for Co-Amoxiclav are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

Organism	Susceptibility Breakpoints (µg/ml)		
	Susceptible	Intermediate	Resistant
<i>Haemophilus influenzae</i> ¹	≤1	-	> 1
<i>Moraxella catarrhalis</i> ¹	≤1	-	> 1
<i>Staphylococcus aureus</i> ²	≤2	-	> 2
Coagulase-negative staphylococci ²	≤0.25		> 0.25
<i>Enterococcus</i> ¹	≤4	8	> 8
<i>Streptococcus A, B, C, G</i> ⁵	≤0.25	-	> 0.25
<i>Streptococcus pneumoniae</i> ³	≤0.5	1-2	> 2
Enterobacteriaceae ^{1,4}	-	-	> 8
Gram-negative Anaerobes ¹	≤4	8	> 8
Gram-positive Anaerobes ¹	≤4	8	> 8
Non-species related breakpoints ¹	≤2	4-8	> 8

¹ The reported values are for Amoxicillin concentrations. For susceptibility testing purposes, the concentration of Clavulanic acid is fixed at 2 mg/l.

² The reported values are Oxacillin concentrations.

³ Breakpoint values in the table are based on Ampicillin breakpoints.

⁴ The resistant breakpoint of R>8 mg/l ensures that all isolates with resistance mechanisms are reported resistant.

⁵ Breakpoint values in the table are based on Benzylpenicillin breakpoints.

The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Commonly susceptible species

Aerobic Gram-positive micro-organisms

Enterococcus faecalis



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

Staphylococcus aureus (methicillin-susceptible)£

Streptococcus agalactiae

*Streptococcus pneumoniae*¹

Streptococcus pyogenes and other beta-hemolytic streptococci

Streptococcus viridans group

Aerobic Gram-negative micro-organisms

Capnocytophaga spp.

Eikenellacorrodens

*Haemophilus influenzae*²

Moraxella catarrhalis

Pasteurellamultocida

Anaerobic micro-organisms

Bacteroidesfragilis

Fusobacteriumnucleatum

Prevotella spp.

Species for which acquired resistance may be a problem

Aerobic Gram-positive micro-organisms

Enterococcus faecium §

Aerobic Gram-negative micro-organisms

Escherichia coli

Klebsiellaoxytoca

Klebsiellapneumoniae

Proteus mirabilis

Proteus vulgaris

Inherently resistant organisms

Aerobic Gram-negative micro-organisms

Acinetobacter sp.

Citrobacterfreundii

Enterobacter sp.

Morganellamorganii

Providencia spp.

Pseudomonas sp.



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

Serratia sp.

Stenotrophomonas maltophilia

§ Natural intermediate susceptibility in the absence of acquired mechanism of resistance.

£ All methicillin-resistant staphylococci are resistant to Co-Amoxiclav.

¹ *Streptococcus pneumoniae* that is fully susceptible to penicillin may be treated with this presentation of Co-Amoxiclav. Organisms that show any degree of reduced susceptibility to penicillin should not be treated with this presentation (see sections 4.2 and 4.4).

² Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.

5.2 Pharmacokinetic properties

Absorption

Amoxicillin and clavulanic acid, are fully dissociated in an aqueous solution at physiological pH. Both components are rapidly and well absorbed by the oral administration. Absorption of Co-Amoxiclav is optimised when taken at the start of a meal. Following oral administration, Co-Amoxiclav are approximately 70% bioavailable. The plasma profiles of both components are similar and the time to peak plasma concentration (T_{max}) in each case is approximately one hour.

The pharmacokinetic results for a study, in which Co-Amoxiclav (250 mg/125 mg tablets three times daily) was administered in the fasting state to groups of healthy volunteers are presented below.

Mean (\pm SD) pharmacokinetic parameters					
Active substance(s) administered	Dose (mg)	C_{max} (μ g/ml)	T_{max} * (h)	AUC _(0-24h) ((μ g.h/ml)	T 1/2 (h)
Amoxicillin					
AMX/CA 250 mg/125 mg	250	3.3 \pm 1.12	1.5 (1.0-2.0)	26.7 \pm 4.56	1.36 \pm 0.56
Clavulanic acid					
AMX/CA 250 mg/125 mg	125	1.5 \pm 0.70	1.2 (1.0-2.0)	12.6 \pm 3.25	1.01 \pm 0.11



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

AMX – amoxicillin, CA – clavulanic acid

* Median (range)

Amoxicillin and clavulanic acid serum concentrations achieved with Co-Amoxiclav are similar to those produced by the oral administration of equivalent doses of amoxicillin or clavulanic acid on their own.

Distribution

About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribution is around 0.3-0.4 l/kg for amoxicillin and 0.2 l/kg for the clavulanic acid.

Following intravenous administration, both amoxicillin and clavulanic acid have been found in the gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus. Amoxicillin does not adequately distribute into the cerebrospinal fluid.

From animal studies there is no evidence for significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk, as with trace quantities of clavulanic acid (see section 4.6).

Both amoxicillin and clavulanic acid have been shown to cross the placental barrier (see section 4.6).

Biotransformation

Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent of up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces and as carbon dioxide in expired air.

Elimination

The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is eliminated by both renal and non-renal mechanisms.

Co-Amoxiclav has a mean elimination half-life of around an hour and a mean total clearance of approximately 25 l/h in healthy subjects. Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

unchanged in urine during the first 6 h after administration of single Co-Amoxiclav 250 mg/125 mg or 500 mg/125 mg tablets. Various studies have found the urinary excretion to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the first 2 hours after administration.

Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid (see section 4.5).

Age

The elimination half-life of amoxicillin is similar for children aged 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

Following oral administration of Co-Amoxiclav to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of either amoxicillin or the clavulanic acid.

Renal impairment

The total serum clearance of Co-Amoxiclav decreases proportionately along with decreasing renal function. The reduction in the drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted via the renal route. Doses in renal impairment must therefore, prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid (see section 4.2).

Hepatic impairment

Hepatically impaired patients should be dosed with caution and hepatic their liver function monitored at regular intervals.



FINECURE PHARMACEUTICALS LIMITED, AHMEDABAD, INDIA

**SOLIDMOX CLAV - 625
CO-AMOXICLAV TABLETS BP**

5.3 Preclinical safety data

Non-clinical data revealed that Co-Amoxiclav causes no special hazard to humans based on studies from safety pharmacology, genotoxicity and toxicity to reproduction.

Repeat dose toxicity studies performed in dogs with Co-Amoxiclav demonstrated gastric irritancy and vomiting, and discolouring of the tongue.

Carcinogenicity studies have not been conducted with Co-Amoxiclav or its components.

6. Pharmaceutical particulars

6.1 List of Excipients

6.2 Incompatibilities

Not applicable

6.3 Shelf life

Unopened: 24 months

6.4 Special precautions for storage

Store in the original package to protect from moisture.

Do not store above 25°C.

6.5 Nature and contents of container

7 tablets are packed in 1 Alu-Alu blister such 2 alu-alu blister packed in the carton along with Insert.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.